Navigation Links
Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R)
Date:7/2/2008

Three new products coming soon to Bioniche's growing line of injectable

products

LAKE FOREST, Ill., July 2 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare Corporation's ENLON product line, including:

-- ENLON(R) (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection 5 mL ampule

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection, 15 mL Multi-dose Vial

Bioniche purchased the rights and certain assets related to the ENLON(R) product line from Baxter, which discontinued ENLON(R) in February 2008. Bioniche anticipates launching all three codes of ENLON(R) in October 2008.

"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.

According to IMS data, 2007 sales of ENLON(R) and ENLON-PLUS(R) totaled $2,727,000 and 307,000 units.

About ENLON(R) and ENLON-PLUS(R)

ENLON(R) is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON(R) is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at http://www.bionichepharma.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)


'/>"/>
SOURCE Bioniche Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
3. Transcept Pharmaceuticals Appoints Key Senior Executives
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
7. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
8. Pharmasset Joins Russell 3000 Index
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
11. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... among radiotherapy patients, prevent chest wall collapses in pre-term infants with respiratory ... receive a total of $600,000 in funding through the ninth round of ...
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and IBM ... into an agreement to develop a cloud based ... providing a holistic view of the multiple influences ... Cognitive Insights could be designed to support shared ... is an innovative nonprofit healthcare organization with 875 ...
(Date:2/18/2017)... Addison, TX (PRWEB) , ... February 17, 2017 ... ... International has officially opened for business in Hong Kong. , Nerium International is ... ™ Formula, and Firming Body Contour Cream, NeriumAD™ Formula to consumers across Hong ...
(Date:2/17/2017)... Feb. 17, 2017  If only one in ... a mutation-conferring resistance to chemotherapy, thousands of cancer ... has focused on finding these mutations in ever-smaller ... circulating tumor DNA in blood — to guide ... Unfortunately, however, detecting these genetic anomalies ...
Breaking Biology Technology:
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/23/2017)... latest mobile market research from Acuity Market Intelligence reveals ... average price of a biometric smartphone decreased from $849 ... are now 120 sub-$150 models on the market at ... a year ago at an average price of $127. ... Acuity Market Intelligence Principal, "Biometric Smartphones are a global ...
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
Breaking Biology News(10 mins):